Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 15/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770654 | 1.00 | EPHX1 (0.50) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL772557 | 0.97 | EPHX2 (0.50) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL769987 | 0.97 | EPHX2 (0.50) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL770637 | 0.92 | EPHX1 (0.48) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL771010 | 0.92 | EPHX1 (0.48) | EPHX1EPHX2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL770270 | 0.90 | KMT2A (0.42) | EPHX1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL771393 | 0.88 | KMT2A (0.41) | EPHX1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL15377790 | 0.86 | KMT2A (0.43) | EPHX2NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL771263 | 0.84 | EPHX1 (0.39) | EPHX1EPHX2 | |
| SCHEMBL771349 | 0.83 | CACNA1H (0.37) | NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822452-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2014-09-02 | — | — | US | disclosed |
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-8524894-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | EPHX1 227/4885EPHX2 1149/4885NPC1 97/4885 |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | EPHX1 232/4885EPHX2 1153/4885NPC1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.